You are here

Article Text

Article menu
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Good outcome after rituximab treatment for a mixed warm and cold autoimmune haemolytic anaemia
  1. Brigitte Granel1,
  2. Pascal Rossi1,
  3. Fanny Bernard1,
  4. Isabelle Dettori2,
  5. Regis Costello3,
  6. Anne Laurence Demoux1,
  7. Denis Bagneres1,
  8. Pierre Lafforgue4,
  9. Yves Frances1
  1. 1
    Hopital Nord, Internal Medicine, Chemin des Bourrely, Marseille, 13915, France
  2. 2
    Etablissement Français du Sang, Boulevard Baille, Marseille, 13385, France
  3. 3
    Hopital Nord, Haematology, Chemin des Bourrely, Marseille, 13915, France
  4. 4
    Hopital Conception, Rheumatology, Boulevard Baille, Marseille, 13385, France
  1. Brigitte Granel, bgranel{at}ap-hm.fr

Summary

Mixed warm and cold autoimmune anaemia is a rare haemolytic anaemia that is commonly associated with lymphoproliferative disorders and autoimmune diseases. Although steroid therapy is the first-line treatment, rituximab represents a good alternative. The present study reports on a successful treatment with rituximab in a young woman suffering from a mixed warm and cold autoimmune haemolytic anaemia associated with a mixed connective tissue disease.

https://doi.org/10.1136/bcr.09.2008.0857

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None.

    • Patient consent: Patient/guardian consent was obtained for publication.